Verano Announces Third Quarter 2025 Financial Results
CHICAGO, Oct. 29, 2025 (GLOBE NEWSWIRE) — Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced its financial results for the third quarter ended September 30, 2025, which were prepared in accordance with U.S. Generally Accepted Accounting Principles (“U.S. GAAP”).
Third Quarter 2025 Financial Highlights
Revenues, net of discounts of $203 million.
Gross profit of $95 million or 47% of revenue.
SG&A expenses of $81 million or 40% of revenue.
Net Loss of $(44) million or (22)% of revenue.
Adjusted EBITDA¹ of $53 million or 26% of revenue.
Net cash provided by operating activities of $26 million.
Capital expenditures of $8 million.
Management Commentary
“This quarter reflects our hard work positioning Verano ahead of long-term growth opportunities by investing in infrastructure, generating efficiencies, improving wholesale and brand performance, and strengthening our capital structure and financial foundation for the future,” said George Archos, Verano founder, Chairman and Chief Executive Officer.
“With more exciting new product innovation planned for the busy retail holiday season, together with our valued partners and talented teams across the country, we look forward to closing the year on a high note and hitting the ground running in what we hope will be a transformative year for Verano and the industry in 2026.”
Third Quarter 2025 Financial Overview
Revenues, net of discounts, for the third quarter 2025 were $203 million, down from $217 million for the third quarter of 2024, and up from $202 million for the second quarter of 2025. The decrease in revenue for the third quarter 2025 compared to the third quarter 2024 was driven primarily by ongoing price compression and competition.
Gross profit for the third quarter 2025 was $95 million or 47% of revenue, down from $109 million or 50% of revenue for the third quarter 2024, and down from $113 million or 56% of revenue for the second quarter 2025. The decrease in gross profit for the third quarter 2025 compared to the third quarter 2024 was due to overall top line revenue declines, increased promotional activity, and an increase in the costs of goods sold due to short-term operational enhancements.
SG&A expenses for the third quarter 2025 were $81 million or 40% of revenue, down from $92 million or 43% of revenue for the third quarter 2024, and down from $86 million or 43% of revenue for the second quarter 2025. The decrease in SG&A expenses for the third quarter 2025 compared to the third quarter 2024 was driven primarily by a decrease in depreciation and amortization and efficiencies generated across the business.
Net loss for the third quarter 2025 was $(44) million or (22)% of revenue, versus $(43) million or (20)% of revenue in the third quarter 2024. The increase in net loss for the third quarter 2025 compared to the third quarter 2024 was primarily driven by an impairment charge of $5 million and legal loss contingencies of $10 million, offset by a lower provision for income taxes compared to the prior year period.
Adjusted EBITDA¹ for the third quarter 2025 was $53 million or 26% of revenue.
Net cash provided by operating activities for the third quarter 2025 was $26 million, down from $30 million for the third quarter 2024, which was primarily attributable to an increase in income tax payments made during the third quarter 2025 compared to the prior year period.
Capital expenditures for the third quarter 2025 were $8 million, down from $57 million for the third quarter 2024, and down from $10 million in the second quarter 2025.
Third Quarter 2025 Operational Highlights
Proposed redomiciling of the Company from British Columbia, Canada to the State of Nevada.
Expanded the Company’s retail footprint by opening MÜV™ Crystal River, the Company’s 82nd dispensary in Florida.
Secured a revolving credit facility of US $75,000,000, from which the Company drew US $50,000,000 to retire US $50,000,000 of higher interest rate debt from its existing senior secured credit facility without incurring any prepayment penalty, with the remaining US $25,000,000 available to draw for strategic initiatives.
Subsequent Operational Highlights
Raised Ohio retail footprint to six locations with the opening of Zen Leaf Antwerp.
Expanded vape product portfolio with exclusive, first-to-market launch of HYPHEN all-in-one pod system.
On October 27th, 2025, the Company’s shareholders approved the redomiciling of the Company to Nevada, and its Board of Directors subsequently approved completing the redomicile.
Due to an employee strike at the British Columbia Registrar of Companies, the Company is unable to provide a definitive date on when the completion will occur, but will plan to finalize the redomicile as expediently as possible.
Current operations span 13 states, comprised of 158 dispensaries and 15 production facilities with more than 1.1 million square feet of cultivation capacity.
Balance Sheet and Liquidity
As of September 30, 2025, the Company’s current assets were $385 million, including cash and cash equivalents of $83 million. The Company had working capital of $242 million and total debt, net of issuance costs, of $401 million.
The Company’s total Class A subordinate voting shares outstanding was 361,815,879 as of September 30, 2025.
Conference Call and Webcast
A conference call and webcast with analysts and investors is scheduled for October 29, 2025 at 8:30 a.m. ET / 7:30 a.m. CT to discuss the results.
The live and archived webcast will be available on the Events and Presentations page of the Company’s investor relations website at investors.verano.com.
The NCV Newswire by New Cannabis Ventures aims to curate high quality content and information about leading cannabis companies to help our readers filter out the noise and to stay on top of the most important cannabis business news. The NCV Newswire is hand-curated by an editor and not automated in anyway. Have a confidential news tip? Get in touch.
Verano Announces Third Quarter 2025 Financial Results
CHICAGO, Oct. 29, 2025 (GLOBE NEWSWIRE) — Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced its financial results for the third quarter ended September 30, 2025, which were prepared in accordance with U.S. Generally Accepted Accounting Principles (“U.S. GAAP”).
Third Quarter 2025 Financial Highlights
Management Commentary
“This quarter reflects our hard work positioning Verano ahead of long-term growth opportunities by investing in infrastructure, generating efficiencies, improving wholesale and brand performance, and strengthening our capital structure and financial foundation for the future,” said George Archos, Verano founder, Chairman and Chief Executive Officer.
“With more exciting new product innovation planned for the busy retail holiday season, together with our valued partners and talented teams across the country, we look forward to closing the year on a high note and hitting the ground running in what we hope will be a transformative year for Verano and the industry in 2026.”
Third Quarter 2025 Financial Overview
Revenues, net of discounts, for the third quarter 2025 were $203 million, down from $217 million for the third quarter of 2024, and up from $202 million for the second quarter of 2025. The decrease in revenue for the third quarter 2025 compared to the third quarter 2024 was driven primarily by ongoing price compression and competition.
Gross profit for the third quarter 2025 was $95 million or 47% of revenue, down from $109 million or 50% of revenue for the third quarter 2024, and down from $113 million or 56% of revenue for the second quarter 2025. The decrease in gross profit for the third quarter 2025 compared to the third quarter 2024 was due to overall top line revenue declines, increased promotional activity, and an increase in the costs of goods sold due to short-term operational enhancements.
SG&A expenses for the third quarter 2025 were $81 million or 40% of revenue, down from $92 million or 43% of revenue for the third quarter 2024, and down from $86 million or 43% of revenue for the second quarter 2025. The decrease in SG&A expenses for the third quarter 2025 compared to the third quarter 2024 was driven primarily by a decrease in depreciation and amortization and efficiencies generated across the business.
Net loss for the third quarter 2025 was $(44) million or (22)% of revenue, versus $(43) million or (20)% of revenue in the third quarter 2024. The increase in net loss for the third quarter 2025 compared to the third quarter 2024 was primarily driven by an impairment charge of $5 million and legal loss contingencies of $10 million, offset by a lower provision for income taxes compared to the prior year period.
Adjusted EBITDA¹ for the third quarter 2025 was $53 million or 26% of revenue.
Net cash provided by operating activities for the third quarter 2025 was $26 million, down from $30 million for the third quarter 2024, which was primarily attributable to an increase in income tax payments made during the third quarter 2025 compared to the prior year period.
Capital expenditures for the third quarter 2025 were $8 million, down from $57 million for the third quarter 2024, and down from $10 million in the second quarter 2025.
Third Quarter 2025 Operational Highlights
Subsequent Operational Highlights
Balance Sheet and Liquidity
As of September 30, 2025, the Company’s current assets were $385 million, including cash and cash equivalents of $83 million. The Company had working capital of $242 million and total debt, net of issuance costs, of $401 million.
The Company’s total Class A subordinate voting shares outstanding was 361,815,879 as of September 30, 2025.
Conference Call and Webcast
A conference call and webcast with analysts and investors is scheduled for October 29, 2025 at 8:30 a.m. ET / 7:30 a.m. CT to discuss the results.
Original press release
Get Our Sunday Newsletter
In This Article:
verano, VRNO, vrnof
Related News:
Cannabis Stocks Could Get Crushed Further
Big Cannabis Companies Are Set to Report Q3 Financials
Don’t Get Excited About the Q3 MSO Financial Reports
Florida’s Medical Cannabis Market Is Struggling